Thursday, October 27, 2011

Lacorene




Lacorene may be available in the countries listed below.


Ingredient matches for Lacorene



Arginine

Arginine aspartate (a derivative of Arginine) is reported as an ingredient of Lacorene in the following countries:


  • Argentina

International Drug Name Search

Tuesday, October 25, 2011

Lybrol




Lybrol may be available in the countries listed below.


Ingredient matches for Lybrol



Bisoprolol

Bisoprolol is reported as an ingredient of Lybrol in the following countries:


  • Croatia (Hrvatska)

International Drug Name Search

Friday, October 21, 2011

Mastrinal




Mastrinal may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Mastrinal



Cloxacillin

Cloxacillin benzathine (a derivative of Cloxacillin) is reported as an ingredient of Mastrinal in the following countries:


  • Switzerland

Neomycin

Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Mastrinal in the following countries:


  • Switzerland

International Drug Name Search

Saturday, October 15, 2011

Famotin




Famotin may be available in the countries listed below.


Ingredient matches for Famotin



Famotidine

Famotidine is reported as an ingredient of Famotin in the following countries:


  • Bangladesh

  • Hong Kong

  • India

  • Singapore

  • Sri Lanka

International Drug Name Search

Epizol




Epizol may be available in the countries listed below.


Ingredient matches for Epizol



Lamotrigine

Lamotrigine is reported as an ingredient of Epizol in the following countries:


  • Romania

International Drug Name Search

Friday, October 14, 2011

Vetrocloricin




In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vetrocloricin



Chloramphenicol

Chloramphenicol is reported as an ingredient of Vetrocloricin in the following countries:


  • United States

International Drug Name Search

Wednesday, October 12, 2011

Zefecort




Zefecort may be available in the countries listed below.


Ingredient matches for Zefecort



Budesonide

Budesonide is reported as an ingredient of Zefecort in the following countries:


  • Greece

International Drug Name Search

Tuesday, October 11, 2011

Bontril Slow-Release


Generic Name: phendimetrazine (Oral route)


fen-dye-MET-ra-zeen TAR-trate


Commonly used brand name(s)

In the U.S.


  • Bontril

  • Bontril PDM

  • Bontril Slow-Release

  • Melfiat

  • Obezine

  • Phendiet

  • Phendiet-105

  • Prelu-2

Available Dosage Forms:


  • Tablet

  • Capsule

  • Capsule, Extended Release

Therapeutic Class: Appetite Suppressant, Centrally Acting


Chemical Class: Phendimetrazine


Uses For Bontril Slow-Release


Phendimetrazine is used as part of a short-term plan, along with a low calorie diet, for weight reduction. It is used in obese patients who have not been able to lose weight with diet and exercise alone. Phendimetrazine belongs to the group of medicines known as appetite suppressants.


This medicine is available only with your doctor's prescription.


Before Using Bontril Slow-Release


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of phendimetrazine tablets in the pediatric population. Safety and efficacy have not been established.


Use of phendimetrazine slow-release capsules is not recommended in children younger than 12 years of age.


Geriatric


No information is available on the relationship of age to the effects of phendimetrazine in geriatric patients.


Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Brofaromine

  • Clorgyline

  • Furazolidone

  • Iproniazid

  • Isocarboxazid

  • Lazabemide

  • Linezolid

  • Moclobemide

  • Nialamide

  • Pargyline

  • Phenelzine

  • Procarbazine

  • Rasagiline

  • Selegiline

  • Sibutramine

  • Toloxatone

  • Tranylcypromine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Agitated state or

  • Arteriosclerosis (hardening of the arteries), advanced or

  • Drug abuse or dependence, history of or

  • Glaucoma or

  • Heart problems (e.g., heart murmur, valvular heart disease) or

  • Hypertension (high blood pressure), moderate to severe or

  • Hyperthyroidism (overactive thyroid)—Should not be used in patients with these conditions.

  • Hypertension (high blood pressure), mild—Use with caution. May make these conditions worse.

Proper Use of phendimetrazine

This section provides information on the proper use of a number of products that contain phendimetrazine. It may not be specific to Bontril Slow-Release. Please read with care.


Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. If too much is taken, it may become habit-forming (causing mental or physical dependence).


This medicine is available in two forms: slow-release capsules and tablets. Ask your doctor which dosage form is right for you.


Carefully follow your doctor's instructions for a reduced-calorie diet plan and regular exercise. Talk with your doctor before starting any exercise program.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For treatment of obesity:
    • For oral dosage form (slow-release capsules):
      • Adults and teenagers—One capsule or 105 milligrams (mg) once a day, taken 30 to 60 minutes before the morning meal.

      • Children younger than 12 years of age—Use is not recommended.


    • For oral dosage form (tablets):
      • Adults—One tablet or 35 milligrams (mg) two or three times a day, taken one hour before meals. Your doctor may adjust your dose as needed. However, the dose is usually not more than 2 tablets three times a day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Bontril Slow-Release


It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and does not cause any unwanted effects.


Do not use phendimetrazine if you are also using similar medicines such as benzphetamine, diethylpropion, mazindol, phentermine, Didrex®, or Suprenza™. Also, do not use this medicine if you have used an MAO inhibitor (MAOI) such as Eldepryl®, Marplan®, Nardil®, or Parnate® within the past 14 days. Using these medicines together may cause serious unwanted effects.


Make sure your doctor knows if you are pregnant or planning to become pregnant before using this medicine.


This medicine may be habit-forming. If you think this medicine is not working properly after you have taken it for a few weeks, do not increase the dose. Instead, check with your doctor.


Stop using this medicine and check with your doctor right away if you notice a decrease in your ability to exercise, if you faint, or if you have chest pain, swelling of your feet or lower legs, or trouble with breathing. These may be symptoms of a very serious heart or lung problem.


This medicine may cause some people to become dizzy, lightheaded, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert.


For diabetic patients: This medicine may affect blood sugar levels. If you notice a change in the results of your blood or urine sugar tests or if you have any questions, check with your doctor.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription and nonprescription (over-the-counter) medicines, dietary supplements, herbal remedies, or medicines for appetite control, asthma, colds, cough, hay fever, and sinus problems.


Bontril Slow-Release Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Rare
  • Seeing, hearing, or feeling things that are not there

  • severe mental changes

Incidence not known
  • Anxiety

  • burning while urinating

  • difficult or painful urination

  • dizziness

  • dry mouth

  • fast, irregular, pounding, or racing heartbeat or pulse

  • feeling of warmth

  • headache

  • hyperventilation

  • increased need to urinate

  • irritability

  • nervousness

  • numbness or tingling in the arms or legs

  • passing urine more often

  • redness of the face, neck, arms, and occasionally, upper chest

  • restlessness

  • shakiness in the legs, arms, hands, or feet

  • shortness of breath

  • sweating

  • trembling or shaking of the hands or feet

  • trouble sleeping

  • trouble thinking, speaking, or walking

  • weakness

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Abdominal or stomach cramps

  • blurred vision

  • change in consciousness

  • convulsions

  • diarrhea

  • discouragement

  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

  • fainting

  • fast, slow, or irregular heartbeat

  • feeling sad or empty

  • lack of appetite

  • lightheadedness

  • loss of consciousness

  • loss of interest or pleasure

  • nausea

  • overactive reflexes

  • panic

  • physical attempt to injure

  • pounding in the ears

  • rapid breathing

  • sweating

  • tiredness

  • trouble concentrating

  • unusual tiredness or weakness

  • violent actions

  • vomiting

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Incidence not known
  • Decreased interest in sexual intercourse

  • difficulty having a bowel movement (stool)

  • inability to have or keep an erection

  • increased in sexual ability, desire, drive, or performance

  • increased interest in sexual intercourse

  • loss in sexual ability, desire, drive, or performance

  • sleeplessness

  • stomach pain

  • unable to sleep

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Friday, October 7, 2011

Zomig


See also: Generic Zomig-ZMT


Zomig is a brand name of zolmitriptan, approved by the FDA in the following formulation(s):


ZOMIG (zolmitriptan - spray; nasal)



  • Manufacturer: ASTRAZENECA

    Approval date: September 30, 2003

    Strength(s): 5MG/SPRAY [RLD]

ZOMIG (zolmitriptan - tablet; oral)



  • Manufacturer: IPR

    Approval date: November 25, 1997

    Strength(s): 2.5MG, 5MG [RLD]

Has a generic version of Zomig been approved?


No. There is currently no therapeutically equivalent version of Zomig available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Indolyl compounds for treating migraine
    Patent 5,466,699
    Issued: November 14, 1995
    Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
    Assignee(s): Burroughs Wellcome Co.
    ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
    Patent expiration dates:

    • November 14, 2012


    • November 14, 2012
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS


    • May 14, 2013
      ✓ 
      Pediatric exclusivity




  • Therapeutic heterocyclic compounds
    Patent 5,863,935
    Issued: January 26, 1999
    Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
    Assignee(s): Zeneca Limited
    ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
    Patent expiration dates:

    • November 14, 2012


    • May 14, 2013
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations containing zolmitriptan
    Patent 6,750,237
    Issued: June 15, 2004
    Inventor(s): Alan Roy; Dearn & Sarah Louise; Williamson & Simon John; Summers & Trevor John; Coomber
    Assignee(s): AstraZeneca AB
    A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
    Patent expiration dates:

    • November 28, 2020
      ✓ 
      Drug product


    • May 28, 2021
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations containing zolmitriptan
    Patent 7,220,767
    Issued: May 22, 2007
    Inventor(s): Dearn; Alan Roy & Williamson; Sarah Louise & Summers; John Simon & Coomber; Trevor John
    Assignee(s): AstraZeneca AB
    A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
    Patent expiration dates:

    • November 28, 2020
      ✓ 
      Drug product


    • May 28, 2021
      ✓ 
      Pediatric exclusivity



See also...

  • Zomig Consumer Information (Drugs.com)
  • Zomig Consumer Information (Wolters Kluwer)
  • Zomig Spray Consumer Information (Wolters Kluwer)
  • Zomig Consumer Information (Cerner Multum)
  • Zomig nasal Consumer Information (Cerner Multum)
  • Zomig Advanced Consumer Information (Micromedex)
  • Zomig AHFS DI Monographs (ASHP)
  • Zolmitriptan Consumer Information (Wolters Kluwer)
  • Zolmitriptan Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Zolmitriptan Spray Consumer Information (Wolters Kluwer)
  • Zolmitriptan Consumer Information (Cerner Multum)
  • Zolmitriptan nasal Consumer Information (Cerner Multum)
  • Zolmitriptan Advanced Consumer Information (Micromedex)
  • Zolmitriptan AHFS DI Monographs (ASHP)

Thursday, October 6, 2011

Liferol




Liferol may be available in the countries listed below.


Ingredient matches for Liferol



Formoterol

Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Liferol in the following countries:


  • Italy

International Drug Name Search

Wednesday, October 5, 2011

Shiomarin




Shiomarin may be available in the countries listed below.


Ingredient matches for Shiomarin



Latamoxef

Latamoxef disodium salt (a derivative of Latamoxef) is reported as an ingredient of Shiomarin in the following countries:


  • Japan

  • Taiwan

International Drug Name Search

Monday, October 3, 2011

Gront




Gront may be available in the countries listed below.


Ingredient matches for Gront



Cilostazol

Cilostazol is reported as an ingredient of Gront in the following countries:


  • Japan

International Drug Name Search